Genetically engineered mice in drug development

Journal of Internal Medicine

Volumn 245, Issue 6, 1999, Pages 627-635

  Livingston, James N ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Drug development; Noninsulin dependent diabetes; Obesity; Transgenic animals

Indexed keywords

ANTIDIABETIC AGENT; DNA; INSULIN;

ANIMAL EXPERIMENT; BIOTECHNOLOGY; CONFERENCE PAPER; DRUG RESEARCH; DRUG TARGETING; GENETIC ENGINEERING; GLUCOSE TRANSPORT SYSTEM; INSULIN RELEASE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; GENETIC ENGINEERING; GLUCOSE; INSULIN; MICE; OBESITY; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 0033057859     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00491.x     Document Type: Conference Paper

References (37)

1. 1 Joshi RL, Lamothe B, Bucchini D, Jami J. Gentically engineered mice as animal models for NIDDM. FEBS Lett 1997; 401: 99-103.
2. 2 Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 1980; 77: 7380-84.
3. 5 Bronson SK, Smithies O. Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 1994; 269: 27155-8.
4. 4 Patti M-E, Kahn CR. Transgenic animal models: insights into the pathophysiology of NIDDM. Diabetes Rev 1997; 5: 149-64.
5. 5 Majzoub JA, Muglia LJ. Molecular medicine: knockout mite. N Engl J Med 1996; 334: 904-7.
6. 6 Gu H, Marth JD, Orban PC, Mossman H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994; 265: 103-6.
7. 7 Marth JD. Recent advances in gene mutagenesis by site-directed recombination. J Clin Invest 1996; 98: 1999-2002.
8. 8 White MG, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1-4.
9. 9 Patti M-F, Sun XJ, Bruning JC, Araki E, Lipes MA, White MF et al. 4PS/IRS-2 is the alternative substrate of the insulin receptor in IRS-1 deficient mice. J Biol Chem 1995; 270: 24670-71
10. 10 Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F et al. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellilus. N Engl J Med 1993; 328: 697-702.
11. 11 Lowell BB, Susulic VS, Hamann A, Lawitts JA, Hinims-Hagen J. Boyer BB et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993; 366: 740-42.
12. 12 Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL, McKnight GS. Genetically lean mice result from targeted disruption of R11β subunit of protein Kinase A. Nature 1996; 182: 622-6.
13. 13 Erickson JC. Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415-18.
14. 14 Klebig ML, Wilkinson JE, Geisler JG, Woychik RP. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes and yellow fur. Proc Natl Acad Sci USA 1995; 92: 4728-32.
15. 15 Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper M-E et al. Targeted disruption of the B3-adrenergic receptor gene. J Biol Chem 1995; 270: 29483-92.
16. 16 Tecott LH. Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-6.
17. 17 Benecke H, Flier JS, Rosenthal N, Siddle K, Klein HH, Moller DE. Muscle specific expression of human insulin receptor in transgenic mice. Diabetes 1993; 42: 206-12.
18. 18 Chang PY, Benecke H, Le Marchand-Brustel Y, Lawitts JA, Moller DE. Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J Biol Chem 1994; 269: 16034-40.
19. 19 Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15: 1542-7.
20. 20 Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nature Genet 1996; 12: 106-9.
21. 21 Araki E, Lipes MA, Patti M-E, Bruning JC, Haag BL III, Johnson RS et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372: 186-90.
22. 22 Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372: 182-6.
23. 23 Houseknecht KL, Zhu AX, Gnudi L, Hamann A, Zierath JR, Tozzo E et al. Overexpression of H-ras selectively in adipose tissue of transgenic mice: evidence for enhanced sensitivity to insulin. J Biol Chem 1996; 271: 11147-55.
24. 24 Moxham CM, Malbon CC. Insulin action impaired by deficiency of the G-protein subunit Gia2. Nature 1996; 379: 840-43.
25. 25 Arrandale JM, Gore-Willse A, Rocks S, Ren J-M, Zhu J, Davis A et al. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 1996: 271: 21353-8.
26. 26 Katz EB, Stenbit AE, Hatton K, DePinho RA, Charron MJ, Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT 4. Nature 1995; 177: 151-5.
27. 27 Rossetti L, Stenbit AE, Katz EB, Barzilai N, Chen W, Hu M et al. Disruption of one allele of the murine GLUT 4 gene causes marked resistance to the action of insulin. J Invest Med 1996; 44: 265A.
28. 28 Gibbs EM, Stock JL, McCoid SC, Stukenbrok HA, Pessin JE, Stevenson RW et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT 4). J Clin Invest 1995; 95: 1512-18.
29. 29 Gulve EA, Ren JM, Marshall BA, Gao J, Hansen PA, Holloszy JO et al. Glucose transport activity in skeletal muscles from transgenic mice overexpresing GLUT 1: increased basal transport is associated with a defective response to diverse stimuli that activates GLUT 4. J Biol Chem 1994; 269: 18366-70.
30. 30 Chang PY, Jensen J, Printz RL, Granner DK, Ivy JL, Moller DE. Overexpression of hexokinase II in transgenic mice. J Biol Chem 1996; 271: 14834-9.
31. 31 Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91: 9151-4.
32. 32 Valera A, Solanes G, Fernandez-Alvarez J, Pujol A, Ferrer J, Asins G et al. Expression of GLUT-2 antisense RNA in B cells of transgenic mice leads to diabetes. J Biol Chem 1994; 269: 28543-6.
33. 33 Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Tukahashi N, Ito K et al. Pancreatic B-cell-specific targeted disruption of glucokinase gene. J Biol Chem 1995; 270: 30253-6.
34. 34 D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD et al. Pancreatic expression and secretion of human islet, amyloid polypeptide in a transgenic mouse. Diabetes 1994; 43: 1457-61.
35. 35 Epstein PN, Overbeck PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989; 58: 1067-73.
36. 36 Kato I, Takasawa S, Akabane A, Tanaka O, Abe H, Takamura T et al. Regulatory Role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic B cells: enhanced insulin secretion in CD38-expressing transgenic mice. J Biol Chem 1995; 270: 30045-50.
37. 37 Marban SL, DeLoia JA, Gearhart JD. Hyperinsulinemia in transgenic mice carrying multiple copies of the human insulin gene. Dev Genet 1989; 10: 356-64.